Drug Research
Drug Discovery & Development

WuXi Biologics, Prima sign non-binding MOU for biologics development

Published 24 November 2016

WuXi Biologics, a WuXi AppTec group company, and Prima Biomed have signed a non-binding MOU to form a strategic biologics development and manufacturing partnership.

Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima's development partner in China, Eddingpharm. WuXi Biologics will also be Prima's preferred partner to manufacture potential new products.

IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe.

Prima BioMed CEO Marc Voigt said, "Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership."

WuXi Biologics CEO Chris Chen said: "We are honored to play a critical role to enable biotech and pharma companies to realize commercialization via WuXi's innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology. 

"WuXi Biologics is committed to producing the highest quality product to enable robust global supply of this potential biologics to patients worldwide."

Source: Company Press Release